Artivion (NYSE:AORT) Price Target Raised to $47.00 at JMP Securities

Key Points

• JMP Securities raised its price target for Artivion from $42.00 to $47.00, indicating a potential upside of 16.57% from its current price.
• The stock has received a mix of ratings, with one analyst rating it a Strong Buy, six giving it a Buy rating, and others assigning Hold and Sell ratings.
• Artivion reported $0.24 earnings per share for the last quarter, surpassing analyst expectations and showing a revenue increase of 15.3% year-over-year.

Artivion (NYSE:AORT - Get Free Report) had its price target hoisted by JMP Securities from $42.00 to $47.00 in a note issued to investors on Friday,Benzinga reports. The brokerage currently has a "market outperform" rating on the stock. JMP Securities' price objective would indicate a potential upside of 16.57% from the company's current price.

AORT has been the topic of a number of other research reports. LADENBURG THALM/SH SH lowered shares of Artivion from a "buy" rating to a "neutral" rating and lifted their price objective for the company from $32.00 to $38.80 in a research note on Wednesday, August 13th. Stifel Nicolaus lifted their price objective on shares of Artivion from $40.00 to $46.00 and gave the company a "buy" rating in a research note on Monday, September 29th. Canaccord Genuity Group raised their price target on shares of Artivion from $41.00 to $50.00 and gave the stock a "buy" rating in a research report on Monday, September 29th. Wall Street Zen raised shares of Artivion from a "hold" rating to a "buy" rating in a research report on Monday, August 25th. Finally, Citigroup reissued an "outperform" rating on shares of Artivion in a research report on Friday. One research analyst has rated the stock with a Strong Buy rating, six have given a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company's stock. Based on data from MarketBeat, the stock has a consensus rating of "Moderate Buy" and a consensus target price of $43.97.

Artivion Trading Down 1.6%

AORT opened at $40.32 on Friday. The firm has a market capitalization of $1.90 billion, a P/E ratio of -96.00 and a beta of 1.67. The firm's 50 day moving average is $41.11 and its 200-day moving average is $32.41. Artivion has a 52-week low of $21.97 and a 52-week high of $45.07. The company has a quick ratio of 3.48, a current ratio of 4.78 and a debt-to-equity ratio of 0.52.

Artivion (NYSE:AORT - Get Free Report) last posted its quarterly earnings data on Thursday, August 7th. The company reported $0.24 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.11 by $0.13. The company had revenue of $112.97 million for the quarter, compared to analyst estimates of $107.96 million. Artivion had a negative net margin of 4.43% and a positive return on equity of 5.70%. The business's quarterly revenue was up 15.3% compared to the same quarter last year. Artivion has set its FY 2025 guidance at EPS. Analysts expect that Artivion will post 0.37 EPS for the current fiscal year.

Insider Buying and Selling at Artivion

In other Artivion news, CEO James P. Mackin sold 12,500 shares of Artivion stock in a transaction on Friday, August 15th. The shares were sold at an average price of $42.32, for a total value of $529,000.00. Following the completion of the transaction, the chief executive officer owned 852,783 shares of the company's stock, valued at $36,089,776.56. The trade was a 1.44% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this link. Also, insider John E. Davis sold 10,802 shares of Artivion stock in a transaction on Tuesday, August 12th. The stock was sold at an average price of $43.67, for a total transaction of $471,723.34. Following the completion of the transaction, the insider directly owned 208,778 shares of the company's stock, valued at approximately $9,117,335.26. This represents a 4.92% decrease in their position. The disclosure for this sale can be found here. In the last three months, insiders sold 74,858 shares of company stock worth $3,250,129. Company insiders own 7.60% of the company's stock.

Institutional Investors Weigh In On Artivion

Several institutional investors have recently bought and sold shares of AORT. Franklin Resources Inc. raised its position in Artivion by 1.9% in the second quarter. Franklin Resources Inc. now owns 29,263 shares of the company's stock worth $910,000 after acquiring an additional 533 shares in the last quarter. Smartleaf Asset Management LLC increased its holdings in Artivion by 47.7% in the second quarter. Smartleaf Asset Management LLC now owns 1,667 shares of the company's stock worth $52,000 after buying an additional 538 shares during the last quarter. Illinois Municipal Retirement Fund increased its holdings in Artivion by 3.1% in the first quarter. Illinois Municipal Retirement Fund now owns 20,519 shares of the company's stock worth $504,000 after buying an additional 611 shares during the last quarter. MCF Advisors LLC increased its holdings in Artivion by 109.3% in the first quarter. MCF Advisors LLC now owns 1,176 shares of the company's stock worth $29,000 after buying an additional 614 shares during the last quarter. Finally, Creative Planning boosted its position in Artivion by 5.6% during the second quarter. Creative Planning now owns 14,272 shares of the company's stock worth $444,000 after purchasing an additional 753 shares during the period. Institutional investors and hedge funds own 86.37% of the company's stock.

About Artivion

Artivion, Inc manufactures, processes, and distributes medical devices and implantable human tissues worldwide. The company provides BioGlue, a polymer consisting of bovine blood protein and an agent for cross-linking proteins for cardiac, vascular, neurologic, and pulmonary procedures; cardiac preservation services; PhotoFix, a bovine pericardial patch; and aortic arch stent grafts including E-vita Open Plus and E-vita Open Neo.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.